Business
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved su...
Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human
About this update from Pasithea Therapeutics Corp.
[{"type":"text","content":"Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor function \n -- PAS-003 is a monoclonal antibody targeting α5/β1 integrin for the treatment of amyotrophic lateral sclerosis (“ALS”) -- -- Lead α5/β1 integrin drug candidate to be selected in H2 2023 -- PALO ALTO, Calif. and MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders, today announced a publication in the internationally renowned scientific peer-reviewed journal Proceedings of the National Academy of Sciences (PNAS), related to its PAS-003 drug discovery program, that describes an increased expression of α5/β1 (α5) integrin on motor neurons in ALS human and mouse tissue, as well as the blockade of this integrin as a potential new approach to treat ALS patients. The study entitled “Elevated α5 integrin expression on myeloid cells in motor areas in amyotrophic lateral sclerosis is a therapeutic target in ALS” can be found here: https://www.pnas.org/doi/10.1073/pnas.2306731120 The paper presents new findings from an interdisciplinary collaboration of scientific teams at Pasithea, the Mayo Clinic, and Oregon Health & Science University, combining results from human post-mortem tissues from ALS patients and from tissue samples from the superoxide dismutase-1 G93A mouse model of ALS (SOD1G93A). Key findings from the publication show: an increased expression of α5 integrin in motor pathways of the central and peripheral nervous system in post-mortem tissues from ALS patients with various clinical ALS phenotypes and disease duration;specificity of α5 integrin in ALS compared to other integrins;presence of α5 integrin-positive microglia, particularly in the zone of active and prior neuronophagia;an increased expression of α5 integrin in microglia and macrophages in the SOD1G93A mouse model of ALS linked to disease progression;the administration of a monoclonal antibody against α5 integrin increased survival in the SOD1G93A mouse model of ALS compared to an isotype ...